Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDK-004
- Development stage
- Discontinued
- Lead developer
- Codiak BioSciences
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
**CDK-004** is an investigational, intravenously administered exosome-based antisense oligonucleotide therapy developed by Codiak BioSciences for solid tumors involving the liver. Also called **exoASO-STAT6**, it consists of cell-derived exosomes loaded with a synthetic lipid-tagged antisense oligonucleotide directed against **STAT6**. The candidate was designed to preferentially deliver the oligonucleotide to tumor-associated myeloid cells, silence STAT6, and reprogram immunosuppressive M2-like macrophages toward a proinflammatory M1-like phenotype, thereby promoting antitumor immune activity. A first-in-human Phase 1 study in advanced hepatocellular carcinoma and liver metastases from colorectal or gastric cancer was terminated. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05375604))
- Other names
- exoASO-STAT6exoASO-STAT-6exoASO-STAT 6
02
Targets
STAT6 (Signal Transducer and Activator of Transcription 6)
Beyond the preview
Go deeper on CDK-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDK-004.